Pacira BioSciences
PCRX
PCRX
180 hedge funds and large institutions have $1.64B invested in Pacira BioSciences in 2017 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 43 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
8% less funds holding
Funds holding: 196 → 180 (-16)
16% less capital invested
Capital invested by funds: $1.97B → $1.64B (-$322M)
34% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 41
Holders
180
Holding in Top 10
6
Calls
$46.7M
Puts
$16.2M
Top Buyers
| 1 | +$51.8M | |
| 2 | +$34.3M | |
| 3 | +$31.8M | |
| 4 |
HM
HealthCor Management
New York
|
+$29.4M |
| 5 |
PC
PointState Capital
New York
|
+$21.3M |
Top Sellers
| 1 | -$87.8M | |
| 2 | -$34.9M | |
| 3 | -$31M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$14.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$12.1M |